שווי פעילות לרווח לפני ריבית, מסים ופחת INmune Bio (INMB)

INmune Bio, Inc. (INMB) is a biotech startup developing anti-brain inflammation treatments for dementia therapy using specific TNF inhibitors. The visualization of financial quotes based on the EV/EBITDA metric stands at 0.00, which complements data regarding management's strategy for conducting clinical trials. Since there are no commercial sales, the asset's market value is based entirely on FDA trial results.

The market views INmune Bio, Inc. (INMB) as a high-risk asset, where calculating business value relative to operating profit allows for the identification of the real debt load without tax distortions. Analyzing the EV/EBITDA multiple reveals the specifics of the biotech sector: the absence of revenue during the clinical trial stage turns this indicator into a marker of the company's dependence on external financing.